Krystal Biotech, Inc. (KRYS)
Biological Products, (No Diagnostic Substances)
Latest Price
$341.12
TTM P/E
45.67
Normalized P/E
350.72
Div Yield
--
Book Value
43.59
P/B Ratio
7.83
Valuation metrics
adjust assumptions →EPS: $6.84
Book value / share: $41.78
Formula: √(22.5 × EPS × BVPS)
Graham Number
$80.18
76% downside
Base FCF: $154M (median of recent 5yr)
Growth: 25%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$409.73
+20% upside
EPS: $6.84
Target P/E: 46×
Formula: EPS × P/E
P/E Fair Value
$314.64
8% downside
Institutional Ownership
96.4% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| FMR LLC | 4.37M | $1.13B | 14.86% | +24.4K | 2026-03-31 |
| BlackRock, Inc. | 3.94M | $1.02B | 13.39% | +2.6K | 2026-03-31 |
| Avoro Capital Advisors LLC | 2.89M | $746.0M | 9.81% | -- | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.46M | $376.0M | 4.95% | -- | 2026-03-31 |
| STATE STREET CORP | 1.31M | $339.0M | 4.47% | -27.9K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.17M | $301.0M | 3.96% | -- | 2026-03-31 |
| Soleus Capital Management, L.P. | 1.15M | $297.0M | 3.92% | +212.0K | 2026-03-31 |
| Capital World Investors | 824.7K | $213.0M | 2.80% | +15.2K | 2026-03-31 |
| Redmile Group, LLC | 673.5K | $173.0M | 2.29% | -4.2K | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 644.0K | $166.0M | 2.19% | +32.1K | 2026-03-31 |